Management
Professor Trevor Jones CBE Ph.D. DSc FKC FPS FRSC Hon FRCP FBPharmcolS, Non-Executive Chairman
Professor Trevor Jones has been Chairman of the ReNeuron Group since February 1999. He recently retired as Director General of the Association of the British Pharmaceutical Industry (ABPI), and was, until 1994, Research & Development Director at Wellcome plc. He has been awarded honorary doctorates from five universities; he has fellowships from Kings College London, the Royal Society of Chemistry, the Royal Pharmaceutical Society of Great Britain, the British Pharmaceutical Society and the Royal College of Physicians and its Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He is a founder member of the Geneva-based public/private partnership Medicines for Malaria and in 2004 he was appointed to the World Innovation and Public Health Organisation on Intellectual Property Rights Health. He sits on the Boards of a number of life science companies including Allergan, Inc.
Michael Hunt BSc ACA, Chief Executive Officer
Michael Hunt joined ReNeuron as Chief Financial Officer and was appointed Chief Operating Officer in September 2003 and Chief Executive Officer in July 2005. Prior to ReNeuron, he spent six years at Biocompatibles International plc where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He is a founding member of the BioIndustry Association's RegenMed Industry Group Advisory Committee, he sits on the BIA's Finance and Tax Advisory Committee and is a working group member of the UK Government's recently established Office for Life Sciences. He read economics at University College London and qualified as a chartered accountant with Ernst & Young in London.
Dr John Sinden BA MA Ph.D, Chief Scientific Officer
Dr. John Sinden is a scientific co-founder of ReNeuron and has been a director of the ReNeuron Group since October 1998. Prior to joining ReNeuron as Chief Scientific Officer in October 1998, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry at Kings College London. He graduated in Psychology from the University of Sydney and completed a Ph.D. in Neuroscience from the University of Paris at the College de France. He subsequently held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987.
Mark Docherty BEng, ACA, Non-Executive Director
Mark Docherty was appointed to the Board in March 2003. He is a chartered accountant and holds a BEng in Mechanical Engineering from Sheffield University. He was a founding director of Merlin Biosciences Limited (now Excalibur Fund Managers Limited) and was actively involved in the structuring and financing of many of the Merlin portfolio companies. Previously, he was a Manager in the Corporate Finance Group of Arthur Andersen. He is also a non-executive director of Biowisdom Limited and Pantherix Limited.
Dr Paul Harper BSc Ph.D., Non Executive Director
Dr. Paul Harper is a graduate of Leeds University (Microbiology/Virology). He initially pursued a career in drug discovery and development with Glaxo Group Research as Head of Antimicrobial Chemotherapy, Johnson and Johnson Limited as Director of Research & Development and with Unipath plc. This was followed by work in a number of start-up companies and SMEs as Chief Executive Officer or adviser. These included, as CEO, preparing Cambridge Antibody Technology PLC for flotation on the London Stock Exchange and founding Provensis Limited to develop a drug device product
Bryan Morton BSc, MBA, Non Executive Director
Bryan Morton is Chief Executive Officer of EUSA Pharma, Inc., a rapidly growing specialty pharmaceutical company he founded in 2006. He is a Non-executive Director of Aircraft Medical Ltd, a medical device company and is a member of the Pilgrim Software global advisory board. He began his pharmaceutical career in sales and has held positions in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry, largely with Merck and Co. Inc. and Bristol Myers Squibb. In 2003, he founded Zeneus Pharma, which was sold to Cephalon Inc. in late 2005 for US$360 million. He has a BSc in Pharmacology from Aberdeen University and a MBA from Durham University.
Dr Kenny Pollock BSc, Ph.D., Head of Cell Development
Dr. Pollock joined ReNeuron Limited in September 2001 as Head of Molecular Pharmacology. In 2002 he took over management of the Cell Biology group and joined the Management Committee in January 2004. As a graduate and post-graduate of Glasgow University (Department of Pharmacology), his core research interests for the last twenty years have been in cell signalling and cell biology. Following post-doctoral posts at the University of Cambridge and with AstraZeneca plc, he worked for eleven years in drug discovery research with Aventis Pharmaceuticals, Inc. Prior to joining ReNeuron, he worked as a project manager with Incyte Corporation developing pharmacogenomics databases. He now manages all internal and external development cell biology projects.
Dr Erik Miljan BSc Ph.D., Head of Stem Cell Research
Dr. Miljan carried out his graduate studies at the University of Western Ontario, Canada, and completed his post-graduate studies at the University of Hong Kong, with a research focus on protein and glycolipid biochemistry of signal transduction. He completed a post-doctoral fellowship position at the Children's Brain Tumor Research Institute, Children's Memorial Hospital, Chicago. He joined ReNeuron in August 2002 to study signal transduction into stem cells, and now manages early stage cell biology to proof-of-concept as well as external discovery science collaborations.
Dr Paul Stroemer BSc Ph.D., Head of Pre-clinical Research
Dr. Stroemer joined ReNeuron in September 1998 as a researcher and since 2004 has been responsible for managing both in-house and contracted pre-clinical development programs. He completed a Ph.D. at the University of Texas Medical Branch in Galveston, developing pharmacotherapies in the promotion of behavioural recovery and anatomical plasticity after stroke. Prior to joining ReNeuron, he undertook post-doctoral research at the University of Manchester examining the neuroprotective effects of reducing inflammatory responses in the brain after stroke.He now manages both internal and external pre-clinical projects.
Professor Jack Price BA Ph.D., Principal Scientific Consultant
Professor Price is Professor of Developmental Neurobiology and Head of the Centre for the Cellular Basis of Behaviour at the Institute of Psychiatry, Kings College London. He obtained a Ph.D. in Neuroscience from University College London before a period of post-doctoral research at the Massachusetts Institute of Technology. He then directed a research group at the National Institute for Medical Research, Mill Hill. He moved to SmithKline Beecham Pharmaceuticals in 1994, where he became Director for Molecular Neurobiology. Since 1998, he has been on the permanent staff of the Institute of Psychiatry and Consultant to ReNeuron Limited.
Top of page